Rituximab as a novel treatment for heart failure: evidence from a case series
- PMID: 31911994
- PMCID: PMC6939812
- DOI: 10.1093/ehjcr/ytz227
Rituximab as a novel treatment for heart failure: evidence from a case series
Comment on
-
Targeting CD20+ B-lymphocytes in inflammatory dilated cardiomyopathy with rituximab improves clinical course: a case series.Eur Heart J Case Rep. 2019 Sep 1;3(3):ytz131. doi: 10.1093/ehjcr/ytz131. Eur Heart J Case Rep. 2019. PMID: 31365055 Free PMC article.
References
-
- Braunwald E. Biomarkers in heart failure. N Engl J Med 2008;358:2148–2159. - PubMed
-
- Aimo A, Castiglione V, Borrelli C, Saccaro LF, Franzini M, Masi S, Emdin M, Giannoni A.. Oxidative stress and inflammation in the evolution of heart failure: from pathophysiology to therapeutic strategies. Eur J Prev Cardiol 2019, Aug 14. [Epub ahead of print]. - PubMed
-
- Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, Glanowska G, Wilczewski P, Niklewski T, Zembala M, Poloński L, Rozek MM, Wodniecki J.. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 2001;104:39–45. - PubMed
Publication types
LinkOut - more resources
Full Text Sources